10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

KRAS2 Antibody (C-term) Blocking Peptide

Synthetic peptide
Catalog # BP16005b

Specification

KRAS2 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession P01116

KRAS2 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 3845

Other Names
GTPase KRas, K-Ras 2, Ki-Ras, c-K-ras, c-Ki-ras, GTPase KRas, N-terminally processed, KRAS, KRAS2, RASK2

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

KRAS2 Antibody (C-term) Blocking Peptide - Protein Information

Name KRAS

Synonyms KRAS2, RASK2

Function
Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:20949621). Plays an important role in the regulation of cell proliferation (PubMed:23698361, PubMed:22711838). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306).

Cellular Location
Cell membrane; Lipid-anchor; Cytoplasmic side. Endomembrane system. Cytoplasm, cytosol

KRAS2 Antibody (C-term) Blocking Peptide - Protocols

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

KRAS2 Antibody (C-term) Blocking Peptide - Images

KRAS2 Antibody (C-term) Blocking Peptide - Background

This gene, a Kirsten ras oncogene homolog from themammalian ras gene family, encodes a protein that is a member ofthe small GTPase superfamily. A single amino acid substitution isresponsible for an activating mutation. The transforming proteinthat results is implicated in various malignancies, including lungadenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreasand colorectal carcinoma. Alternative splicing leads to variantsencoding two isoforms that differ in the C-terminal region.

KRAS2 Antibody (C-term) Blocking Peptide - References

Bruckman, K.C., et al. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110(5):632-637(2010)Wong, K.K., et al. Am. J. Pathol. 177(4):1611-1617(2010)Irahara, N., et al. Diagn. Mol. Pathol. 19(3):157-163(2010)Carotenuto, P., et al. Pharmacogenomics 11(8):1169-1179(2010)Leventopoulos, G., et al. Clin. Exp. Rheumatol. 28(4):556-557(2010)